04.24.20 -- Strategies To Address Viral Vector Manufacturing

The increasing scrutiny over the cost of biopharmaceuticals, combined with the need to bring lifesaving therapies to emerging regions, requires businesses to balance social and financial needs while driving patient access. Utilizing standardized approaches to biomanufacturing can lower costs, improve outcomes, and alter the landscape of the global pharmaceutical market.

Small and emerging companies pursuing new therapeutic indications often struggle with a wide range of drug development financial demands while managing with limited resources. Learn how a small biotech company completed an economic evaluation of manufacturing options to ensure it was selecting the best fit for its drug development needs. 

A key component of gene therapy is the use of viral vectors for in vivo and ex vivo gene transfer, which are used in approximately 70 percent of cell and gene therapies under trial. Accelerating the production of your viral vector-based therapy requires understanding the strategies and cost-efficiencies available to address the viral vector manufacturing shortage.

The viral vector market is highly active, and the interest in production technologies is driven by recent approvals in cell and gene therapies. These scalable and cost-efficient processes for GMP manufacturing environments address viral vector manufacturing challenges.

The journey from research lab to market is a long one, and most drug candidates do not make it. For those that do progress to market there are many regulatory milestones and hurdles. Here are some tips to assist with up-front planning to prevent headaches down the road.